PurMinds NeuroPharma

PurMinds NeuroPharma

  • Founded: 2020
  • Location: Toronto, ON
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: TBI, Parkinson's, ALS
  • Drug types: NEU, X_X
  • Lead product: PUR001A
  • Product link: https://www.purminds.com/the-purprecision-platform
  • Funding: not disclosed



job board

Short description:

Neuro Drug Discovery

Drug notes:

PUR001B Clin0 brain injury, neurodegenerative diseases; PUR002 Clin0 stroke, Parkinson's

Long description:

PurMinds NeuroPharma is developing disease-modifying therapeutics for neurological conditions. Psychedelic compounds have a bad reputation, however they offer much potential for treating neurological conditions due to their neuroplasticity effects. PurMinds owns and operates a portfolio of assets and licenses enabling them to produce, sell and export psychedelic compounds including psilocybin, MDMA, LSD and DMT. Using their PurPrecision practice, PurMinds is using a data-driven approach to validate therapeutics and stratify patient recruitment in clinical trials. PurMinds lead candidate, PUR101, is a botanical psilocybin formulation that is going through preclinical stages to treat patients with depression in neurological disorders.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com